An observational study in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Novartis Pharmaceuticals. Recruiting at 12 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hemoglobinuria, Paroxysmal by Novartis — 5 open to participants now, 7 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Novartis.
Among the 16 studies in Hemoglobinuria, Paroxysmal by Novartis, this one is one of 2 that started in 2026, is one of 7 observational ones, and was the 15th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 48 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →5 of the 16 studies in Hemoglobinuria, Paroxysmal by Novartis are open now, in 8 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 18–99
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 3 more countries
Ages 2–18
Novartis Pharmaceuticals · Sites in China
Ages 18–80
Novartis Pharmaceuticals · Sites in United States
Ages 18–99
By country, each count listing its studies:
Of the 29 Hemoglobinuria, Paroxysmal studies recruiting now, 13 (45%) set no upper age limit and 11 (38%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 50 is below the median of 90 across 37 observational studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 28 across the 8 interventional studies, 80 across the 7 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
2 of the studies in Hemoglobinuria, Paroxysmal by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT06931691Novartis PharmaceuticalsA Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China | 2027-04-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Hemoglobinuria, Paroxysmal by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates iptacopan effectiveness and safety in routine clinical practice, with a focus on hematological response, transfusion avoidance, and patient-reported outcomes.
The primary objective of the REAL-CARE study is to is to assess the long-term hematological response following iptacopan initiation. This will be assessed through the absolute change in hemoglobin (Hb) levels at 12 months post-initiation, and the proportion of patients who remain free from red blood cell (RBC) transfusions, prescribed as per local requirement and based on Investigator's judgment, from Day 14 through Month 12 after starting iptacopan.
This is a local, multicenter, observational study with retrospective, retro-prospective and prospective cohorts. Adult patients with PNH either naïve to iptacopan or transitioning from the Managed Access Program (MAP) starting from January 2023 will be enrolled. Primary data will be collected prospectively; secondary data will be retrieved retrospectively from patients previously treated under MAP. A mix of primary and secondary data will be collected in retro-prospective patients. Patients will be indexed on the date of iptacopan initiation and will be followed up for 24 months or until iptacopan discontinuation (due to occurrence of an adverse event, lack of efficacy etc), clinical decision, death, administrative issues, consent withdrawal or loss to follow-up, whichever comes first. The enrollment period is planned to last 15 months, with potential adjustments based on enrollment progress. No treatment decision will be influenced by study participation.
No extra visits, examinations, or procedures are imposed. Questionnaires should be collected at the indicated timepoints whenever possible, but, since the administration of the questionnaires represents an additional procedure not included in routine clinical care, these timepoints are considered indicative only, and patients will not be recalled specifically to complete questionnaires if a routine clinical visit is not scheduled.
Italian population of adult patients with PNH either naïve to iptacopan or transitioning from the Managed Access Program (MAP) starting from January 2023
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
1.Concomitant participation in an interventional clinical study related to PNH or its treatment.
No other inclusion/exclusion criteria apply other than the requirements stated in the Summary of Product Characteristics (SmPC).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with iptacopan
absolute change in Hb level post iptacopan initiation
12-month absolute change in hemoglobin (Hb) level post iptacopan initiation
Time frame: 12 months
Proportion of patients with no RBC transfusions
12-month proportion of patients with no Red Blood Cells (RBC) transfusions, prescribed as per local requirement and based on Investigator's judgment, after Day 14.
Time frame: 12 months
Socio-demographic and clinical variables of Paroxysmal Nocturnal Hemoglobinuria population
Descriptive measures of the socio-demographic variables, proportion of PNH cells, clinical symptoms, laboratory parameters, concomitant diseases and treatments and outcomes of PNH patients at iptacopan initiation.
Time frame: date of iptacopan start, day 0
Absolute change in Hb level post iptacopan initiation
24-month absolute change in Hb level post iptacopan initiation
Time frame: date of iptacopan start (day 0), 24 months
Proportion of patients who didn't need RBC transfusion
24-month proportion of patients who didn't need RBC transfusion, prescribed as per local requirement and based on Investigator's judgment, post iptacopan initiation
Time frame: 24 months
Proportion of patients with Hb levels ≥ 12 g/dL AND no RBC transfusion
12- and 24-month proportion of patients with Hb levels ≥ 12 g/dL AND no RBC transfusion, prescribed as per local requirement and based on Investigator's judgment, between Day 14 and month 12 or month 24
Time frame: 12 month, 24 month
Proportion of patients with change in Hb levels ≥ 2 g/dL post iptacopan initiation AND no RBC transfusion
12- and 24-month proportion of patients with change in Hb levels ≥ 2 g/dL post iptacopan initiation AND no RBC transfusion, prescribed as per local requirement and based on Investigator's judgment, between Day 14 and month 12 or month 24
Time frame: 12 month, 24 month
Average number of RBC transfusion
Average number of RBC transfusion, prescribed as per local requirement and based on Investigator's judgment, per patient during 12- and 24-months post iptacopan initiation
Time frame: 12 months and 24 months
Percentage change in LDH level post iptacopan initiation
12- and 24-month percentage change in LDH level post iptacopan initiation.
Time frame: date of iptacopan start (day 0), month 12, month 24
Change in reticulocyte count post iptacopan initiation.
12- and 24-month change in reticulocyte count post iptacopan initiation.
Time frame: date of iptacopan start (day 0), month 12, month 24
Absolute change in bilirubin level post iptacopan initiation.
12- and 24-month absolute change in bilirubin level post iptacopan initiation.
Time frame: date of iptacopan start (day 0), month 12, month 24
Frequency of adverse events (AE) and serious adverse events (SAE) over 12 and 24 months of follow-up
Frequency of adverse events (AE) and serious adverse events (SAE) over 12 and 24 months of follow-up post iptacopan initiation
Time frame: 12 months and 24 months
Proportion of BTH occurrence
Proportion of Breakthrough Hemolysis (BTH) occurrence over 12 and 24 months of follow-up post iptacopan initiation
Time frame: 12 months and 24 months
Type and proportion of Infections occurrence over 12 and 24 months of follow-up
Type and proportion (count and percentage) of Infections occurrence over 12 and 24 months of follow-up post iptacopan initiation
Time frame: 12 months and 24 months
Type and proportion of major adverse vascular events (MAVEs) occurrence
Type and proportion of major adverse vascular events (MAVEs) occurrence over 12 and 24 months of follow-up post iptacopan initiation
Time frame: 12 months and 24 months
Type and proportion of new comorbidities
Type and proportion of new comorbidities occurred within 12 and 24 months of follow-up post iptacopan initiation
Time frame: 12 months and 24 months
Type and proportion of concomitant medications newly prescribed
Type and proportion of concomitant medications newly prescribed during 12 and 24 months of follow-up post iptacopan initiation
Time frame: 12 months and 24 months
Absolute change in Medication Adherence Report Scale - 5 item (MARS-5) scores
The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of five items, each rated on a 5-point Likert Scale, from 0 ("Always") to 5 ("Never"). Items evaluate behaviors such as forgetting to take medications, altering the dose or stopping the treatment. The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment.
Time frame: date of iptacopan start (day 0), month 12 and month 24
Absolute change from iptacopan initiation in PROMIS-29+2 score.
The Patient-Reported Outcomes Measurement Information System (PROMIS) Profile-29+2 is a validated standardized patient reported outcome measure to assess generic health-related quality of life. The questionnaire covers the following nine health domains: Physical function, Anxiety, Depression, Fatigue, Sleep disturbance, Ability to participate in social roles and activities, Pain interference, Cognitive function and Pain intensity. The recall period for all items is the past 7 days. Each of the first eight domains is assessed through 4 items using a 5-point Likert scale. Pain intensity is measured with a single item on an 11-point numeric rating scale from 0 ("no pain") to 10 ("worst imaginable pain"). Each domain is scored separately, with T-scores used to represent the severity or level of functioning in each area. Higher scores can indicate either better health (e.g., physical function) or greater severity of symptoms (e.g., anxiety, depression).
Time frame: date of iptacopan start (day 0), month 12 and month 24
Absolute change from iptacopan initiation in WPAI:SHP score.
Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) is a validated patient-reported outcome measure designed to assess the impact of a specific health problem on work and daily activities. In this study, the questionnaire has been customized for PNH. It includes six questions grouped into four key domains: Absenteeism (work time missed due to PNH), Presenteeism (impairment while working due to PNH), Overall work productivity loss (combined absenteeism and presenteeism), Activity impairment (impact of PNH on regular daily activities outside of work). The recall period is the past 7 days. Responses are used to calculate the percentage of work time missed and the level of impairment experienced by the patient. Higher scores represent greater impairment and reduced productivity.
Time frame: date of iptacopan start (day 0), month 12 and month 24
Number of hospitalizations, emergency room visits, and hospital-based outpatient visits attributable to the management of AEs related to the study treatment
Healthcare resources utilization: The number of hospitalizations, emergency room visits, and hospital-based outpatient visits attributable to the management of adverse events (AEs) related to the study treatment will be documented.
Time frame: Up to 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Aug 2028, 31 months after the start.
Of 23 observational studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 245. This study's planned 31 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.